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Abstract: Liver transplantation remains an essential procedure for many patients suffering from
alcoholic liver disease. Alcohol use monitoring remains paramount all through the stages of this
complex process. Direct alcohol biomarkers, with improved specificity and sensibility, should replace
traditional indirect markers. Phosphatidylethanol (PEth) has been recently tested in alcoholic liver
disease patients, but more evidence is needed, especially in comparison with other direct biomarkers.
We conducted an observational study among patients awaiting liver transplantation. We analyzed
Peth in blood, ethylglucuronide (EtG) in hair and urine and ethylsulphate (EtS) in urine, using mass
spectrometry methods. In addition, transaminases, and self-reports were analyzed. A total of 50
patients were included (84% men, mean age 59 years (SD = 6)). 18 patients (36%) screened positive
for any marker. Self-reports were positive in 3 patients. EtS was the biomarker with more positive
screens. It also was the most frequently exclusive biomarker, screening positive in 7 patients who
were negative for all other biomarkers. PEth was positive in 5 patients, being the only positive
biomarker in 2 patients. It showed a false negative in a patient admitting alcohol use the previous
week and screening positive for EtG and EtS. Hair EtG was positive in 3 patients who had negative
Peth, EtG. EtG did not provide any exclusive positive result.A combination of biomarkers seems to
be the best option to fully ascertain abstinence in this population. Our study suggest EtS might also
play a significant role.
Keywords: liver transplatation; phosphatidylethanol; ethylglucuronide; alcohol dependence
1. Introduction
Alcoholic liver disease (ALD) remains the most frequent etiology in life-threatening liver disease
in a majority of European countries and the US [1,2]. Despite some controversies [3,4], especially in
acute hepatitis unresponsive to medical treatment [5], liver transplantation (LTX) is a well established
and valuable procedure in ALD, especially in end-stage cirrhosis [6,7].
One of the critical issues surrounding LT in alcohol patients is abstinence monitorization, since
abstinence seems to be the gold standard when it comes to treatment aims. That partly explains
the 6-month abstinence rule frequently required prior to LT. Again, the rule does not come without
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controversy [8–10], with some authors arguing in favor of a more dimensional evaluation of the relapse
risk, instead of a binary and time-constrained assessment [11].
Therefore, it seems almost self-evident that in a majority of ALD patients undergoing or waiting
for LT, abstinence assessment and monitorization remains critical, and also challenging. Traditional
indirect alcohol biomarkers remain far from accurate [12–14]. Moreover, they are easily affected by
other medical conditions and variables such as age and sex. On the other hand, self-reports frequently
tend to underreport drinking [15–18].
In this regard, direct alcohol biomarkers (i.e., biomarkers formed in the presence of ethanol) have
consistently demonstrated a better diagnostic validity, both in terms of sensitivity and specificity, for
the monitorization of abstinence [19,20].
The two most validated biomarkers in ALD patients have been ethylglucuronide (EtG) and
phosphatydilethanol (PEth). Two studies conducted with EtG clearly showed its better accuracy
compared to traditional biomarkers [16,17]. Also, when compared to self-reports, EtG disclosed a
higher rate of drinking. Similarly, PEth has been tested in two studies with ALD patients [21,22],
and two studies including both pre- and post-transplant patients [23,24]. Globally, they all seem to
suggest that PEth provides significant added value to monitorization procedures in ALD patients,
since, similarly to other direct alcohol biomarkers, PEth displays a higher sensitivity when compared
to self-reports or traditional, non-direct biomarkers. Also, it can be obtained directly from blood,
which makes it much less prone to contamination or manipulation. However, more studies with more
patients are needed to confirm these preliminary results. Also, more direct comparisons between
direct alcohol biomarkers in these populations are also warranted to better evaluate the diagnostic
performance of the different direct alcohol biomarkers. Here, we present the results of an observational
study conducted among liver transplant candidates undergoing psychiatric evaluation and abstinence
monitoring. The main objective of the study was to evaluate the frequency of a positive PEth result in
this population, as well as comparing PEth performance to that of other biomarkers, especially EtS,
EtG in urine and hair.
2. Methods
2.1. Study Design
This was a single-center, cross-sectional study conducted in a big urban tertiary hospital in
Barcelona, Spain, between November 2017 and January 2019. Results were completely anonymous
and patients were reassured about the information being confidential, so their responses are not being
shared with any clinical members of the research team, nor with the transplant program personnel.
Ethics approval was obtained from the Clinic Hospital Ethics Committee. All participants signed
informed written consents before study enrollment.
2.2. Study Population and Procedure
Patients with alcoholic liver disease must attend a psychiatric consultation before being enrolled
in the transplantation list, usually conducted in an outpatient facility. The attending psychiatrist was
responsible for consecutively offering study participation to eligible patients.
In order to be eligible, patients had to be diagnosed with an alcohol use disorder and alcoholic
liver disease, and be willing to sign informed written consent. Upon acceptance, patients completed
the Alcohol Use Disorder Identification Test (AUDIT) [25] and the Timeline Follow Back (TLFB) [26] for
the preceding 28 days. The AUDIT is a 10-item screening tool widely used to assess drinking amount,
frequency and consequences. For screening purposes, a cut-off of 8 is normally established between
low and medium risk. The TLFB is a calendar method used to retrospectively record all the alcohol
units ingested in the preceding 28 days. After that, blood and urine samples were obtained. If possible,
hair samples were also extracted.
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2.3. Biomarker Assessment
PEth 16:0/18:1 and PEth 16:0/18:2 were analyzed in Dried Blood Spots (DBS) from venous blood
(20 µL). D5-PEth 16:0/18:1 and D5-PEth 16:0/18:2 were used as internal standards. DBS were stored at
−20 ◦C (range of storage time from 7 to 90 days).
Deuterated standards were synthesized in our laboratory from PC 16:0/18:1 and PC 16:0/18:2
and D6-ethanol catalyzed by phospholipase D (Schröck et al., 2016a). For DBS 15 preparation, 20 µL
of whole blood were pipetted on filter cards (GR2261004, PKI 226 Bioanalysis Card, Perkin Elmer,
Rodgau, Germany) and were dried for a minimum of 3 h prior to extraction. PEth was extracted from
DBS with 500 µL of methanol (10 min). The supernatant was transferred to a vial and evaporated to
dryness under a stream of nitrogen at 50 ◦C. The residue was redissolved in 200 µL of mobile phase
A (ammonium acetate (10 mM)/acetonitrile (30:70, v/v)). An aliquot of 80 µL was injected into the
online-SPE-LC-MS/MS system. A previously published validated method for PEth analysis in whole
blood samples was modified for DBS by use of a calibration range of 20–2000 ng/mL (Schröck et
al., 2016b). Limits of quantitation (LoQ) for PEth 16:0/18:1 and PEth 16:0/18:2 were 20 ng/mL. The
analysis was performed with a QTrap 3200 tandem mass spectrometer with a turbo ionspray source
(Sciex, Toronto, Canada). After trapping with a Synergi Polar-RP column (20 × 2 mm, 5 µm) the
two homologues were separated with a Luna RP-C5 column (50 mm × 2 mm, 5 µm) (Phenomenex,
Brechbühler, Schlieren, Switzerland) by gradient elution. Similarly, EtG and EtS were analyzed with
online-SPE-LC-MS/MS system, after being obtained from urine samples.
The method used for extraction of the hair samples has been described previously (Kerekes 2013).
After cleaning hair with water and acetone, pulverization and incubation for 2 h in an ultrasonic bath,
a solid phase extraction was performed with OASIS Max Columns (Waters). After derivatization with
heptafluorobutyric anhydride analysis was performed by GC-MS/MS in negative chemical ionization
mode. The monitored ion transitions were m/z 596/213 (quantifier) and 397/213 (qualifier) for EtG,
and m/z 601/213 for EtG-D5. Limit of detection (LOD) was 0.05 pg/mg hair and a lower limit of
quantification (LLOQ) 0.2 pg/mg hair (Capelle 2015). Gamma-glutamyltransferase (γ-GT), alanine
aminotransferase (ALT) and aspartate aminotransferase were also analyzed.
2.4. Statistical Analysis
Data were analyzed using SPSS (Version 23.0, SPSS Inc., Chicago, IL, USA). All metric parameters
are expressed as total numbers, % or mean ± standard deviation.
3. Results
A total of 50 patients were consecutively included between December 2017 and October 2018. The
mean age of participants was 59 years (SD = 6). A majority (84%) were men. A total of 13 participants
had HCV (26%), and one participant had chronic HBV infection. HIV was present in two patients, and
a lifetime history of drug use was recorded in 7 patients (14%).
Regarding alcohol screening results, 32 (64%) subjects were negative for all biomarkers. That left a
total of 18 (36%) patients screening positive for any of the available markers. Table 1 shows differences
for the main assessments between AUDIT positive and negative patients. Table 2 shows the main
features of the study biomarkers.
A total of 3 patients self-reported alcohol consumption in the previous 28 days. Equally, only
these three patients reported alcohol use during the previous week. Figure 1 shows a box-plot
depicting self-reported duration of abstinence in months. Figure 2 shows a dotplot depicting AUDIT
scores. Figure 3 shows the total number of positives, as well as the number of exclusive positives for
each biomarker.
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Table 1. Differences between AUDIT negative and positive patients for the main variables of the study.
Variable AUDIT negative (score <8) AUDIT positive (score ≥8)
Sex (% men) 83.3 87.5
Age (years) 56.8 53.6
ASAT (mean (SD)) 47.6 (20) UI/L 34.6 (4) UI/L
ALAT (mean (SD)) 34.9 (25) UI/L 33 (28) UI/L
GGT (mean (SD)) 89.9 (86) UI/L 75.6 (11) UI/L
EtG positive (%) 2.4% 62.5%
EtS positive (%) 19.5% 62.5%
PeTH positive (%) 7.1% 25%
HEtG positive (%) 3.4% 66.7%
TLFB positive (%) 0% 37.5%
All biomarkers negative (%) 76.2% 37.5%
Other drugs used (%) 11.9% 25%
VHC (%) 28.6% 25%
AUDIT: alcohol use disorder identification test; ASAT: aspartate aminotransferase; ALAT: alanine aminotransferase;
GGT: gammaglutil transferase; EtG: ethylglucuronide; EtS: ethylsulfate; PeTH: phosphatydilethanol, HEtG: hair
ethylglucuronide; TLFB: timeline follow back.
Table 2. Main characteristics of the study biomarkers.
Biomarker Characteristics References
EtG
Obtained from urine. Sensible to
urine infections and reduced
kidney function. Suitable for
abstinence monitoring.
Time-frame of detection up to a
few days. Cut-off 0.5 mg/L
[15–17,19,20,27–30]
EtS
Obtained from urine. Sensible to
urine infections and reduced
kidney function. Suitable for
abstinence monitoring.
Time-frame of detection up to a
few days. Cut-off 0.05 mg/L.
[17,19,20,31–33]
PeTH
Obtained from dried blood spots.
Suitable for abstinence and heavy
drinking monitoring. Timeframe
of detection from days to weeks.
Cut-off 20 ng/mL
[19,21–24]
HEtG
Obtained from hair. Sensible to
contamination and extraction
methods. Suitable for abstinence
monitoring over long periods of
time. Timeframe of detection from
weeks to months. Cut-off 7 pg/mL.
[19]
EtG: ethylglucuronide; EtS: ethylsulfate; PeTH: phosphatydilethanol, HEtG: hair ethylglucuronide.
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Figure 1. Box-plot showing self-reported abstinence duration (in months).
Figure 2. Dotplot showing Alcohol Use Disorder Identification Test (AUDIT) scores.
Figure 3. Barchart showing total and exclusive positives for each biomarker. EtG: ethylglucuronide;
EtS: ethylsulfate; PeTH: phosphatydilethanol, HEtG: hair ethylglucuronide; TLFB: timeline follow back.
EtS was the biomarker with more positive screens. It also was the most frequently exclusive
biomarker, screening positive in 7 patients who were negative for all other biomarkers. Specifically about
PEth, it was positive in 5 cases. It showed a false negative in a patient admitting alcohol use the
previous week and screening positive for EtG and EtS.
Hair EtG was positive in 3 patients who had negative Peth, Etg and EtS (although one of them
could not provide urine due to renal failure). TLFB and EtG did not provide an exclusive positive result.
J. Clin. Med. 2020, 9, 3060 6 of 9
4. Discussion
Assessment of the drinking status is of paramount importance all through the transplantation
process. Although protocols may vary between regions and individual differences may preclude fully
accurate predictions, it seems reasonable to believe that abstinence before transplantation improves
the probabilities of post-transplant abstinence and compliance [31].
On the other hand, return to drinking after transplantation has been clearly linked to transplantation
failure, allograft fibrosis and finally allograft loss [32], Therefore, the use of highly sensitive and specific
alcohol direct biomarkers seems warranted in this population.
In our study, a selected population awaiting liver transplantation with relatively stable levels
of transaminases and ggt, we found that 36% of the patients screened positive for at least one of the
available biomarkers. Our major findings were: The most frequently positive biomarker was EtS,
followed by EtG and PEth. Peth was positive in 5 patients, showing a false negative result in a patient
admitting drinking the previous week and screening positive for EtG and EtS. These results diverge
somehow from previous studies in the same population ([23], where PEth was the most frequent
positive biomarker. Unfortunately, the study by Fleming and colleagues [24] did not analyze any other
biomarker besides PEth and therefore no comparisons are possible. That being said, they find a 20% of
positive PEth samples, which doubles our 10%, although relevant differences in sample size should be
noted. Interestingly, the rates of positive self-report are similar (8 vs. 6%). Something to consider is the
fact that we used 20 ng/mL as the cut-off or limit of quantification for PEth. Maybe with a lower cut-off
there would have been no false negative. However, most of the literature about PEth is consistent with
the 20 ng/mL as the most useful cut-off.
It is also worth looking at differences between AUDIT positive and negative patients.
Not surprisingly, AUDIT positive patients had a higher rate of positive biomarkers. Actually,
given the stigma that comes with alcohol dependence and the social desirability of self reports [33],
one could consider biomarkers especially useful when self-reports are negative. It is also important to
note that sensibility and specificity for biomarkers taking AUDIT results as the gold standard were
not calculated, since this was not a validation study. While that could be seen as a limitation, it may
also be considered an approach to real clinical situations where the drinking status of patients is not
known beforehand. It is in that scenario where the combination of biomarkers and self-reports must
be used in order to accurately evaluate patients, and in the case of liver transplantation candidates,
make the appropriate decisions. Also worth emphasizing, indirect biomarkers such as transaminases
and GGT values did not show any significant differences (actually were slightly higher for AUDIT
negative patients).
It is also interesting to compare our study with a recently conducted study among the same population
in our clinic [34]. It was a longitudinal study with several months follow-up. Alcohol screening, though,
was performed only with self-reports and ethanol screening in urine specimens. Up to 76% of patients
screened positive at least once during follow-up. This number is larger than the proportion we found
in our study, although it must be stated that ours had a transversal, single point assessment design. It
could be argued that when low sensitivity biomarkers (such as ethanol or indirect blood parameters
like MCV, CDT or transaminases) are used, several months are needed to detect all cases of drinking,
whereas with new direct alcohol biomarkers, a single point assessment is enough to capture the reality of
this population, where not all patients are abstinent despite the importance attributed by both patients
and professionals. This is indeed crucial since biomarker testing in ALD patients should not be viewed,
neither by patients nor professionals, as a decision rule to exclude patients from being transplanted, but
rather as a tool for early detection and treatment of drinking [27].
Head-to-head comparison between biomarkers remains difficult in this and similar studies
conducted among liver transplant candidates, since these are not controlled studies where the amount
of drinking ingested is known beforehand. That leads to the question whether all biomarker positive
results are valid, clinical positive results. In this regard, we believe it is important to pay attention to
EtS, since it was the most frequent positive test, and especially since it was the only positive biomarker
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in 7 patients (14% of the sample). Two previous studies testing PEth in liver transplant candidates did
not include EtS testing [23,24]. Previous studies comparing EtG and EtS in the same population seem
to have shown a good, even larger sensitivity for EtS compared to EtG [17]. That being said, there are
also studies suggesting PEth could be more sensitive than EtS, although they have not been performed
in liver transplant candidates [28].
False positive results are always an important concern, especially with alcohol-containing hand
sanitizers and foods. However, with highly sensitive analysis methods such as LS/MS, the probability
of such events is low [29], and it seems that EtS might be even more accurate than EtG in the distinction
between ethanol ingestion and dermal exposure [35]. Another important consideration is the highly
variable formation and degradation kinetics between individuals regarding EtG and EtS [30]. Moreover,
some recent evidence points out toward a greater stability of EtS in human fluids when compared to
EtG and PEth [36].
Worth mentioning, other authors such as Andreasen–Streichert and colleagues [23], in their liver
transplant biomarkers study, considered single positive biomarkers not backed up by self-reports or
any other biomarker as false positive results. While this might be a conservative approach in clinical
settings, we think this might be too restrictive for research purposes.
One of the main limitations that must be stated in this and similar studies is its cross-sectional
nature, where follow-up information is not gathered. As has been shown previously, this could lead to
relevant information and accurate predictive values [37].
All in all, and similar to other clinical populations, a combination of biomarkers seems to be
the best choice when trying to assess drinking status. Although self-reports must always be taken
into account, they should always be complemented with biomarkers. The evidence gathered in this
study suggests that EtS might have a significant role, as it could increase the overall sensitivity of the
screening in liver transplant candidates.
5. Conclusions
In line with previous literature, this study suggest new direct alcohol biomarkers improve the
monitorization of alcohol use disorder patients. Specifically with liver transplant candidates, direct
biomarkers seem to provide more accurate information regarding drinking status, a fact of paramount
importance for the proper management of such patients.
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